Literature DB >> 33169205

HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study.

Mohamad O Ahmed1, Rachel E Byrne2, Agnieszka Pazderska1, Ricardo Segurado3, Weili Guo2, Anjuli Gunness1, Isolda Frizelle1, Mark Sherlock1, Khalid S Ahmed1, Anne McGowan1, Kevin Moore1, Gerard Boran4, Fiona C McGillicuddy2, James Gibney5.   

Abstract

AIMS/HYPOTHESIS: The prevalence of atherosclerosis is increased in type 1 diabetes despite normal-to-high HDL-cholesterol levels. The cholesterol efflux capacity (CEC) of HDL is a better predictor of cardiovascular events than static HDL-cholesterol. This cross-sectional study addressed the hypothesis that impaired HDL function contributes to enhanced CVD risk within type 1 diabetes.
METHODS: We compared HDL particle size and concentration (by NMR), total CEC, ATP-binding cassette subfamily A, member 1 (ABCA1)-dependent CEC and ABCA1-independent CEC (by determining [3H]cholesterol efflux from J774-macrophages to ApoB-depleted serum), and carotid intima-media thickness (CIMT) in 100 individuals with type 1 diabetes (37.6 ± 1.2 years; BMI 26.9 ± 0.5 kg/m2) and 100 non-diabetic participants (37.7 ± 1.1 years; 27.1 ± 0.5 kg/m2).
RESULTS: Compared with non-diabetic participants, total HDL particle concentration was lower (mean ± SD 31.01 ± 8.66 vs 34.33 ± 8.04 μmol/l [mean difference (MD) -3.32 μmol/l]) in participants with type 1 diabetes. However, large HDL particle concentration was greater (9.36 ± 3.98 vs 6.99 ± 4.05 μmol/l [MD +2.37 μmol/l]), resulting in increased mean HDL particle size (9.82 ± 0.57 vs 9.44 ± 0.56 nm [MD +0.38 nm]) (p < 0.05 for all). Total CEC (14.57 ± 2.47%CEC/4 h vs 12.26 ± 3.81%CEC/4 h [MD +2.31%CEC/4 h]) was greater in participants with type 1 diabetes relative to non-diabetic participants. Increased HDL particle size was independently associated with increased total CEC; however, following adjustment for this in multivariable analysis, CEC remained greater in participants with type 1 diabetes. Both components of CEC, ABCA1-dependent (6.10 ± 2.41%CEC/4 h vs 5.22 ± 2.57%CEC/4 h [MD +0.88%CEC/4 h]) and ABCA1-independent (8.47 ± 1.79% CEC/4 h vs 7.05 ± 1.76% CEC/4 h [MD +1.42% CEC/4 h]) CEC, were greater in type 1 diabetes but the increase in ABCA1-dependent CEC was less marked and not statistically significant in multivariable analysis. CIMT was increased in participants with type 1 diabetes but in multivariable analysis it was only associated negatively with age and BMI. CONCLUSIONS/
INTERPRETATION: HDL particle size but not HDL-cholesterol level is independently associated with enhanced total CEC. HDL particle size is greater in individuals with type 1 diabetes but even after adjusting for this, total and ABCA1-independent CEC are enhanced in type 1 diabetes. Further studies are needed to understand the mechanisms underlying these effects, and whether they help attenuate progression of atherosclerosis in this high-risk group. Graphical abstract.

Entities:  

Keywords:  HDL particle size; HDL-cholesterol efflux capacity; Type 1 diabetes

Mesh:

Substances:

Year:  2020        PMID: 33169205     DOI: 10.1007/s00125-020-05320-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  44 in total

1.  Glycemic control and excess mortality in type 1 diabetes.

Authors:  Marcus Lind; Ann-Marie Svensson; Annika Rosengren
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

Review 2.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Circulation       Date:  2014-08-11       Impact factor: 29.690

3.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

Review 4.  HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Nat Rev Cardiol       Date:  2011-02-08       Impact factor: 32.419

Review 5.  Importance of different pathways of cellular cholesterol efflux.

Authors:  Patricia G Yancey; Anna E Bortnick; Ginny Kellner-Weibel; Margarita de la Llera-Moya; Michael C Phillips; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-23       Impact factor: 8.311

6.  Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis.

Authors:  Johannes Noe; Gerd A Kullak-Ublick; Wolfram Jochum; Bruno Stieger; Reinhold Kerb; Michael Haberl; Beat Müllhaupt; Peter J Meier; Christiane Pauli-Magnus
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

7.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

8.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

Review 9.  Regulation of reverse cholesterol transport and clinical implications.

Authors:  Daniel J Rader
Journal:  Am J Cardiol       Date:  2003-08-18       Impact factor: 2.778

10.  Cooperative transcriptional activation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 genes by nuclear receptors including Liver-X-Receptor.

Authors:  Su Sun Back; Jinsu Kim; Daehyung Choi; Eui Sup Lee; Soo Young Choi; Kyuhyung Han
Journal:  BMB Rep       Date:  2013-06       Impact factor: 4.778

View more
  5 in total

Review 1.  High Density Lipoproteins and Diabetes.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

Review 2.  Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies.

Authors:  Qiao Jin; Ronald Ching Wan Ma
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

Review 3.  HDL functionality in type 1 and type 2 diabetes: new insights.

Authors:  M John Chapman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-04-01       Impact factor: 3.243

4.  HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.

Authors:  Damien Denimal; Serge Monier; Isabelle Simoneau; Laurence Duvillard; Bruno Vergès; Benjamin Bouillet
Journal:  Cardiovasc Diabetol       Date:  2022-08-12       Impact factor: 8.949

Review 5.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.